EVELYN MENDOZA, M.D.
Specialist · HEMET, CA
Individual Active NPI 1558368605
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 791 | 323,267 | $22,132,923 | $8,594,690 | $6,842,694 |
| 2023 | 941 | 417,893 | $10,006,192 | $7,798,950 | $6,192,837 |
| 2022 | 993 | 397,052 | $9,445,565 | $7,183,686 | $5,704,139 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | 41,250 | $1 | $1 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 20,880 | $49 | $39 |
| J0897 | Injection, denosumab, 1 mg | 19,800 | $25 | $20 |
| J9271 | Injection, pembrolizumab, 1 mg | 17,600 | $56 | $45 |
| J0185 | Injection, aprepitant, 1 mg | 17,420 | $2 | $1 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 17,398 | $0 | $0 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 16,640 | $8 | $6 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 10,800 | $6 | $4 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 8,830 | $47 | $37 |
| J1437 | Injection, ferric derisomaltose, 10 mg | 4,600 | $20 | $16 |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 4,218 | $64 | $51 |
| J9041 | Injection, bortezomib, 0.1 mg | 3,138 | $2 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Specialist | 174400000X | ✓ | A48611 | CA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Specialist providers in California
- NPI 1245396191
- NPI 1184820987
- NPI 1811193618
- NPI 1447455423
- NPI 1235224049
- NPI 1730385535
- NPI 1154516664
- NPI 1750650982
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.